[Role of GP IIb/IIIa blockers in clinical cardiology].
Platelet aggregation and thrombosis play a key role in the pathogenesis of unstable coronary syndromes and their ischemic complication. The platelet glycoprotein (GP) IIb/IIIa receptor represents the final common pathway leading to platelet aggregation. In the last 10 years agents that block the GP IIb/IIIa receptor has been developed and tested on a large number of large-scale, randomized trials showing that these drugs, particularly when administered in intravenous form, reduce morbidity and death in patients with acute coronary syndromes and those undergoing percutaneous intervention.